About the trial

The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell Non-Hodgkin’s Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but then comes back again (relapsed B-NHL).

B-NHL is a type of cancer that develops inside or outside of lymph nodes (glands) and organs such as the liver or spleen. It is very difficult to cure children with relapsed or refractory B-NHL. The medicines used now are very powerful with many side effects and only cure around one in every three children treated. It is very important that we quickly find better medicines for these children.

Trial Design

The Glo-BNHL trial will include three groups of children and young people, each given a new medicine (either alone or with chemotherapy). We are looking to make sure the new medicines are safe and that they work to treat the cancer. If the medicine in one group does not work for a child in the trial, then they may be able to join a different group to have another new medicine.

Experts from around the world will carefully pick the medicines most likely to be helpful to be part of the trial. If one of the new medicines seems not to be working as well as hoped then we will take it out of the trial. This will let other new medicines be added to the trial to be tested. If a medicine does seem to be working well, then it will continue in the trial to make sure it really is the most useful medicine we have.

Children from around the world will be invited to take part in the trial. We will then check on them for at least two years to look for possible side effects of the new medicine.

Aims of the trial

  • Test the how well new medicines work to improve the outcomes of children, adolescents and young adults with relapsed or refractory B-NHL (alone or combined with existing treatments)
  • Test the safety of these new medicines in children, adolescents and young adults with relapsed or refractory B-NHL
  • Carry out biological studies to find out how and why some cancers are unaffected by treatment and find possible targets for new medicines

For more information on how to get involved, and for a list of which hospitals are currently recruiting patients to this trial, please visit how to get involved